ArticleBriefings in bioinformatics2025
SageTCR: a structure-based model integrating residue- and atom-level representations for enhanced TCR-pMHC binding prediction.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Artificial intelligence for translational personalized neoantigen cancer vaccine development.Journal of biomedical science · 2026Review
- Structure-based TCR-pMHC binding prediction and generalization to unseen peptides.npj drug discovery · 2026Article
- Modeling TCR-Epitope Recognition Specificity: What We Should Learn to Succeed.Immunological reviews · 2026Review
- Computational prediction of TCR cross-reactivity: principles, challenges and translational opportunities.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
T-cell receptors (TCRs) recognize peptide-MHC (pMHC) complexes through intricate structural interactions, which is a core component of adaptive immunity. However, the diverse and cross-reactive nature of TCRs poses great challenges for accurate prediction of TCR-epitope interactions, hampering the advancement and broad application of TCR-related therapies. Here, we present SageTCR, a bi-level graph neural network (GNN) framework that leverages structural data to predict TCR-pMHC binding possibilities. Harnessing the pretrained language models, SageTCR encodes detailed structural arrangement at both residue-level and atomic-level and effectively integrates the bimodal representations via attention mechanisms. To tackle the deficiency of experimental structures, we explore comprehensive data augmentation strategies to enrich the training and increase the generalizability while concurrently preserving the characteristic TCR-pMHC diagonal binding mode. SageTCR demonstrates superior performance compared to six methods with different deep learning architectures. Furthermore, SageTCR offers the interpretability by identifying and focusing on the conformational features of pivotal contact residues on the interface, which can provide valuable insights for TCR engineering and immunotherapy design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.